Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · iShares

iShares U.S. Pharmaceuticals ETF (IHE)

Ticker IHE · Since 2006-05-01 · · Holdings as of Jun 30, 2026

Expense ratio
0.37%$37/yr per $10k
5-yr return
+9.1%annualized
1-yr return
+31.7%as of Dec 2025
Net assets
$1.1Ball share classes
Holdings
59

Bottom line

Is IHE a good fund? The bottom line

IHE is a managed health care sector ETF from iShares.

Annual fees run 0.37% — about $37 a year on every $10,000 invested, cheaper than 87% of health care sector funds we track.

It returned +31.7% over one year, +9.1% a year over five years, +6.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.1 billion in net assets and 59 holdings, its largest position is Johnson & Johnson (22.4%) and the top 10 make up 79.5% of the portfolio.

What stands out

  • Low cost: cheaper than 87% of health care sector peers
  • 5-year return beat 96% of category peers

What to watch

  • Concentrated: top 10 holdings are 79.5% of assets

Updated Nov 19, 2026

What IHE invests in

The iShares U.S. Pharmaceuticals ETF (the Fund ) seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector.

The Fund seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index (the Underlying Index ), which measures the performance of the pharmaceuticals sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC (the Index Provider or SPDJI ). The Underlying Index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The Underlying Index may include large-, mid- or small-capitalization companies. As of March 31, 2026, a significant portion of the Underlying Index was represented by securities of companies in the healthcare and pharmaceuticals industries or sectors. The components of the Underlying Index are likely to change over time. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund. BFA uses a representative sampling indexing…

From the fund's prospectus (filed Jul 27, 2026).

IHE performance

Fund calendar-year total returns, 2015–2025 2015: +8.8%; 2016: −11.7%; 2017: +10.7%; 2018: −7.7%; 2019: +15.5%; 2020: +13.8%; 2021: +12.8%; 2022: −4.8%; 2023: +1.0%; 2024: +8.1%; 2025: +31.7% +9% 2015 −12% 2016 +11% 2017 −8% 2018 +15% 2019 +14% 2020 +13% 2021 −5% 2022 +1% 2023 +8% 2024 +32% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
IHE+31.7%+9.1%+6.2%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full IHE performance history →

What IHE costs

On a $10,000 investment, IHE's 0.37% expense ratio costs about $37 a year. The prospectus estimates $468 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full IHE fee table →

IHE top 10 holdings

#Holding% of fund
1Johnson & Johnson22.44%
2Eli Lilly And Company22.25%
3BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares6.24%
4Merck & Co., Inc.4.55%
5Bristol-myers Squibb Company4.37%
6Royalty Pharma Plc4.34%
7Viatris Inc.4.22%
8Pfizer Inc.3.96%
9Zoetis Inc.3.73%
10Jazz Pharmaceuticals Public Limited Company3.45%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 79.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to IHE

More funds like IHE →

IHE FAQ

What is the expense ratio of IHE?
IHE's expense ratio is 0.37%, which works out to about $37 a year for every $10,000 invested. The prospectus estimates total costs of $468 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is IHE a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 87% of health care sector peers; 5-year return beat 96% of category peers; concentrated: top 10 holdings are 79.5% of assets. This is general information, not personalized advice.
What does IHE hold?
IHE's largest holdings are Johnson & Johnson (22.4%), Eli Lilly And Company (22.2%), BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (6.2%), Merck & Co., Inc. (4.5%), Bristol-myers Squibb Company (4.4%). It holds 59 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is IHE's 5-year return?
IHE returned +9.1% a year over the five years ending Dec 31, 2025, and +6.2% a year over ten years. Past performance does not guarantee future results.
Who manages IHE?
IHE is offered by iShares through iSHARES TRUST.